First-line therapy for young patients with CLL
نویسندگان
چکیده
منابع مشابه
Chronic lymphocytic leukemia (CLL): first-line treatment.
For the past ten years, there has been a dynamic development of new therapeutic compounds and prognostic parameters for chronic lymphocytic leukemia (CLL). Hematologists and oncologists are challenged to use these new possibilities for an optimized, risk- and fitness-adapted treatment strategy, with the goal of achieving long-term remissions and preserving a good quality of life. This review is...
متن کاملFirst-line and second-line antiretroviral therapy.
January, 2004, administration of measles vaccine was recommended between 12 and 24 months of age, instead of between 12 and 15 months when children have the greatest risk of contracting measles. There is no established system to check vaccination status on entry to the school systems. Strong political and social desire has to be inspired, and vigorous educational campaigns for policy makers and...
متن کاملShould atrial fibrillation ablation be considered first-line therapy for some patients? Why Atrial Fibrillation Ablation Should Be Considered First-Line Therapy for Some Patients
Atrial fibrillation (AF) is an increasingly common disease that affects patient morbidity and mortality. To date, treatments of AF have been frustrating, serving at best to palliate this arrhythmia. AF ablation, on the other hand, has emerged as a promising new treatment strategy. In contrast to rate control or antiarrhythmic drugs, ablation offers the possibility of a lasting cure. When ablati...
متن کاملFirst line therapy for metastatic pancreatic cancer.
Metastatic pancreatic cancer remains a difficult disease to treat; however, there are more new drug combinations on the horizon each week. We will discuss the results of the MPACT trial presented at the 2013 ASCO Annual Meeting (Abstracts #4005, #4058, and #4059) and compare to the 2011 FOLFIRINOX data.
متن کاملPaclitaxel and epirubicin as first-line therapy for patients with metastatic breast cancer.
Paclitaxel (Taxol), has aroused considerable interest for its high single-agent activity in breast cancer and novel mechanism of action. Epirubicin (Farmorubicin), the 4'epimer of doxorubicin (Adriamycin), also has high activity in breast cancer, with the advantage of a lower rate of toxic side effects-especially cardiac effects-compared with its parent compound. The combination of paclitaxel a...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Hematology
سال: 2016
ISSN: 1520-4391,1520-4383
DOI: 10.1182/asheducation-2016.1.146